- Review
Considerations for Augmenting Aripiprazole Long-Acting Injectables with Other Antipsychotics: A Mini-Review
- Jonathan Shaw,
- Ethan Kim,
- Emily Ton,
- Charles Lai,
- Peter Bota and
- Tina Allee
Aripiprazole is a third-generation antipsychotic, approved in 2002, notable for its partial agonism of the Dopamine D2 receptor and lower risk of metabolic and extrapyramidal adverse effects. It is available in a long-acting injectable formulation, w...

